Bio-Techne

Court Revokes Two Advanced Cell Diagnostics Patents, Dismisses Infringement Claims Against Molecular Instruments and Orders Advanced Cell Diagnostics to Make Payment of £1.35 Million to Molecular Instruments

Retrieved on: 
Mardi, mai 21, 2024
Professional Services, Health, Technology, Legal, Nanotechnology, Health Technology, Biotechnology, High court, Judgement, Bio-Techne, European Patent Convention, Patents Court, Research

Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company; NASDAQ: TECH) both be revoked; (2) that Advanced Cell Diagnostics’ infringement claims against Molecular Instruments are dismissed; and (3) that Advanced Cell Diagnostics make a costs payment of £1.35 million (approximately $1.72 million at the current exchange rate) to Molecular Instruments.

Key Points: 
  • Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company; NASDAQ: TECH) both be revoked; (2) that Advanced Cell Diagnostics’ infringement claims against Molecular Instruments are dismissed; and (3) that Advanced Cell Diagnostics make a costs payment of £1.35 million (approximately $1.72 million at the current exchange rate) to Molecular Instruments.
  • In a 2022 lawsuit filed at the High Court of England and Wales (proceedings no.
  • HP-2022-000026), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringed European Patents (UK) 2,500,439 and 1,910,572.
  • “We are pleased that the UK matter is now concluded,” said Dr. Harry Choi, CEO of Molecular Instruments.

BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)

Retrieved on: 
Mardi, mai 7, 2024
RUO, Good manufacturing practice, Safety, Expansion, RNA, Cell, Research, Bio-Techne, Small, Science, Patient, Gene, Society, Medicine, Messenger, Good, GMP, Vaccine

MINNEAPOLIS, May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

Key Points: 
  • MINNEAPOLIS, May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.
  • We will also feature our "Immune Cell Therapy Workflow" multimedia experience, which enables attendees to explore how Bio-Techne's solutions streamline and accelerate the immune cell processing workflow.
  • The topics covered will include characterizing biodistribution and safety of cell and gene therapies, protein analytics strategies for gene therapy, and advancements in closed systems and non-viral cell engineering for immune cell therapy manufacturing.
  • "Bio-Techne's portfolio plays a critical role in the development of next-generation cell and gene therapies.

BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

Retrieved on: 
Mardi, avril 30, 2024
Science, Executive, Universidad, Bristol Myers Squibb, Research, Bio-Techne, Merck & Co., Novartis, Therapy, SVP, Merck

MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024.

Key Points: 
  • MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024.
  • Dr. Klimovsky will serve as a member of the Science and Technology Committee.
  • Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent.
  • "We are pleased to welcome Dr. Klimovsky to our board," said Bob Baumgartner, Chairman of the Board of Bio-Techne.

BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC

Retrieved on: 
Lundi, avril 29, 2024
Protein, Laboratory, Health, Neuroscience, Partnership, Fisher Scientific, Research, Bio-Techne, Thermo Fisher Scientific, Antibody, Biotechnology

Effective May 1, 2024, Bio-Techne will enter into a strategic distribution agreement with Thermo Fisher Scientific, a leading provider of laboratory products and services, in Europe.

Key Points: 
  • Effective May 1, 2024, Bio-Techne will enter into a strategic distribution agreement with Thermo Fisher Scientific, a leading provider of laboratory products and services, in Europe.
  • Under this agreement, Thermo Fisher, through the European arm of its Fisher Scientific Channel, will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins, Immunoassay kits, reagents and enzymes to laboratories and research institutions across Europe.
  • This distribution agreement underscores Thermo Fisher's dedication to fostering innovation and collaboration within the scientific community.
  • For more information about the Fisher Scientific Channel in Europe and its comprehensive range of laboratory products and services, visit their Website .

Court Finds Advanced Cell Diagnostics Patents Invalid in Lawsuit with Molecular Instruments

Retrieved on: 
Mercredi, avril 24, 2024
Research, Medical Devices, Medical Supplies, Genetics, Biotechnology, Health, Pharmaceutical, Other Science, Science, High court, European Patent Convention, Patents Court, Bio-Techne, Court, Judgement

Molecular Instruments, Inc. announced today that the Patents Court of the High Court of England and Wales has found two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company) to be invalid.

Key Points: 
  • Molecular Instruments, Inc. announced today that the Patents Court of the High Court of England and Wales has found two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company) to be invalid.
  • HP-2022-000026), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European Patents (UK) 2,500,439 and 1,910,572.
  • The Court has rejected that claim ruling that both patents are invalid ( https://caselaw.nationalarchives.gov.uk/ewhc/pat/2024/898 ) with Mr. Justice Meade finding that Molecular Instruments' primary evidence (on invalidity) is "really overwhelming in this case."
  • “Our goal is to empower biologists, bioengineers, drug developers, and diagnostics developers by providing them with next-generation molecular tools that enable breakthroughs in their projects,” said Dr. Harry Choi, CEO of Molecular Instruments.

BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS

Retrieved on: 
Mardi, avril 23, 2024
ISH, Trial, Investment, Research, Bio-Techne, COMET, Unified Patent Court, Acquisition, Intellectual property, ACD

MINNEAPOLIS, April 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.

Key Points: 
  • Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology research and clinical applications.
  • RNAscope is the most referenced technology in the industry, with its rapidly growing portfolio of peer-reviewed publications recently surpassing 10,000.
  • In its lawsuit filed in the Unified Patent Court (a pan-European forum for resolving patent disputes), in the Netherlands Local Division of the Court of First Instance in The Hague, Bio-Techne alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439.
  • The lawsuit seeks damages and injunctive relief requiring Molecular Instruments to stop infringing ACD's patents in key European markets.

Nikon Instruments Inc. and Bio-Techne announce partnership to expand access to innovative spatial biology services

Retrieved on: 
Jeudi, mars 28, 2024
Nikon, Health, Drug discovery, Partnership, Research, Bio-Techne, Disease, Diagnosis, Workflow, Nikon Instruments, Microscope

MELVILLE, N.Y., March 28, 2024 /PRNewswire/ -- Nikon Instruments Inc. (Nikon) is pleased to announce that they have entered into a partnership with Lunaphore , part of Bio-Techne Corporation's Spatial Biology Division, to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.

Key Points: 
  • MELVILLE, N.Y., March 28, 2024 /PRNewswire/ -- Nikon Instruments Inc. (Nikon) is pleased to announce that they have entered into a partnership with Lunaphore , part of Bio-Techne Corporation's Spatial Biology Division, to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
  • Through this partnership, in addition to access to the COMET™ platform, Nikon will be able to provide its customers with access to HORIZON™ , Lunaphore's image analysis software designed for analyzing COMET™ hyperplex images, to further streamline image analysis workflow.
  • Researchers and clinicians can leverage the COMET™ platform by Lunaphore to unlock the full potential of spatial biology for their research objectives.
  • "Spatial biology is a dynamic area of innovation that will shed new light on healthcare and further our understanding of human disease and health."

BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES

Retrieved on: 
Jeudi, mars 28, 2024
Health, COMET, Drug discovery, Partnership, Research, Bio-Techne, Disease, Diagnosis, Workflow, Nikon Instruments, Microscope

MINNEAPOLIS, March 28, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore , part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.

Key Points: 
  • MINNEAPOLIS, March 28, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore , part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
  • Together, Lunaphore and the Nikon BioImaging Lab will be able to leverage their complementary expertise in microscopy-based imaging and analysis to bring COMET technology and spatial biology to the greater scientific community.
  • Researchers and clinicians can leverage the universal end-to-end product suite to unlock the full potential of spatial biology for their research objectives.
  • "Spatial biology is a dynamic area of innovation that will shed new light on healthcare and further our understanding of human disease and health."

BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA

Retrieved on: 
Vendredi, mars 22, 2024
Certification, Acute leukemia, Kit, BCR-ABL, Patient, CML, Class, Bio-Techne, Sale, Cancer, IVDR, Diagnosis, Workflow, ABL1, Safety, Liquid biopsy, TKI, Physician, IVDD, Medical device

MINNEAPOLIS, March 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.

Key Points: 
  • Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.
  • The QuantideX qPCR BCR-ABL IS Kit gives labs a robust and reliable tool for monitoring chronic myeloid leukemia (CML) patients.
  • The highly sensitive qPCR-based in vitro diagnostic test quantifies BCR-ABL1 and ABL1 transcripts in blood samples from patients with CML to determine their response to tyrosine kinase inhibitor (TKI) therapy.
  • CML patients must undergo regular monitoring to ensure that they continue to receive the most appropriate treatment for their cancer.

BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS

Retrieved on: 
Lundi, janvier 29, 2024
Patient, Research, Bio-Techne, Bladder cancer, Mass meeting, RNA, Poster, Workflow, Protein, Biomarker, Data analysis, Messenger, COMET, Publication, ACD, Vaccine

MINNEAPOLIS, Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow. Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays. ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform.

Key Points: 
  • Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using industry-leading RNAscope™ technology.
  • MINNEAPOLIS, Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD) , a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow.
  • Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays.
  • ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform.